THE NEUROPROTECTION CAUSED BY PHYTOCANABINOIDS, THEIR EFFECTS AND THEIR APPLICABILITY IN BRAZIL
A NEUROPROTEÇÃO CAUSADA (Português (Brasil))

Keywords

Phytocannabidioids, Neuroprotection, Endocannabidioid System.

How to Cite

Eduarda Serafim Crispim, M. ., de Ávila Lins da Cunha Lima, J. ., Braga Santos, G. ., Ribeiro Coutinho de Mendonça Furtado, F. ., & Ribeiro Coutinho de Mendonça Furtado, B. . (2022). THE NEUROPROTECTION CAUSED BY PHYTOCANABINOIDS, THEIR EFFECTS AND THEIR APPLICABILITY IN BRAZIL. Advanced Studies on Health and Nature, 4, 150–164. https://doi.org/10.51249/easn04.2022.783

Abstract

Introduction: The endocannabinoid system is composed of cannabinoid receptors type 1 (CB1) and type 2, their endogenous agonists, anandamide endocannabinoids and 2-aaquidonoilglycerol (2-AG). It is assumed that 2-AG is the binding receptor of cannabidioids to the Central Nervous System. CB1 inhibits the release of GABA and glutamate from pre-sinaptic terminals, being responsible for the ability to modulate neurotransmission as a mechanism of neuroprotection of CB1 against excitotoxicity. This action provides a good justification for such mechanisms to be investigated as therapeutic targets for severe neurodegenerative diseases, including Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. Development: Cannabidiol is more related to neuroprotective activity, tolerable at higher doses and less cardiovascular and psychological risks, THC to psychotropic effects, since there are medications that contain both substances, there should be a control of its prescription and care for self-medication. Final Considerations: Although we know that cannabidiol has an impact and medicinal value, more studies need to be done, and there should be greater rigor on composition and concentrations, due to the high power of interaction with other substances and their toxic power when used erroneously. Finally, it is known of its beneficial potential for various neurodegenerative diseases.

https://doi.org/10.51249/easn04.2022.783
A NEUROPROTEÇÃO CAUSADA (Português (Brasil))

References

BRUCKI, Sonia Maria Dozzi et al. Cannabinoids in Neurology-Position paper from Scientific Departments from Brazilian Academy of Neurology. Arquivos de neuro-psiquiatria, v. 79, p. 354-369, 2021.

BASAVARAJAPPA, Balapal S. et al. Endocannabinoid system in neurodegenerative disorders. Journal of neurochemistry, v. 142, n. 5, p. 624-648, 2017.

BHATIA-DEY, Naina; HEINBOCKEL, Thomas. Endocannabinoid-mediated neuromodulation in the olfactory bulb: Functional and therapeutic significance. International journal of molecular sciences, v. 21, n. 8, p. 2850, 2020.

ZOU, Shenglong; KUMAR, Ujendra. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. International journal of molecular sciences, v. 19, n. 3, p. 833, 2018.

DI MARZO, Vincenzo; PISCITELLI, Fabiana. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics, v. 12, n. 4, p. 692-698, 2015.

OŻAROWSKI, Marcin et al. Cannabidiol in neurological and neoplastic diseases: Latest developments on the molecular mechanism of action. International journal of molecular sciences, v. 22, n. 9, p. 4294, 2021.

Âmbito Jurídico. A legalização do Uso do Canabidiol e Tetrahidrocanabidiol no Brasil à Luz do Direito Humano à Saúde. Disponível em: https://ambitojuridico.com.br/cadernos/direito-constitucional/a-legalizacao-do-uso-do-canabidiol-e-tetrahidrocanabidiol-no-brasil-a-luz-do-direito-humano-a-saude/ Acesso em: 27 out. 2021.

BRASIL. Câmara dos Deputados. Projeto de Lei no 399/15, de 08 de junho de 2021. Comissão aprova proposta para legalizar no Brasil o cultivo de Cannabis sativa para fins medicinais. Brasília: Câmara dos Deputados, 2021. Disponível em: https://www.camara.leg.br/noticias/769630-comissao-aprova-proposta-para-legalizar-no-brasil-o-cultivo-de-cannabis-sativa-para-fins-medicinais Acesso em : 27 out. 2021.

DOS REIS ROSA FRANCO, Graziella; SMID, Scott; VIEGAS, Cláudio. Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases. Current Neuropharmacology, v. 19, n. 4, p. 449-464, 2021.

HUESTIS, Marilyn A. et al. Cannabidiol adverse effects and toxicity. Current neuropharmacology, v. 17, n. 10, p. 974-989, 2019.

CASSANO, Tommaso et al. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Frontiers in pharmacology, v. 11, p. 124, 2020.

SILVESTRO, Serena et al. Molecular targets of cannabidiol in experimental models of neurological disease. Molecules, v. 25, n. 21, p. 5186, 2020.

OBERBARNSCHEIDT, Thersilla; MILLER, Norman S. The impact of cannabidiol on psychiatric and medical conditions. Journal of clinical medicine research, v. 12, n. 7, p. 393, 2020.

MAROON, Joseph; BOST, Jeff. Review of the neurological benefits of phytocannabinoids. Surgical neurology international, v.9, 2018.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...